small-molecule therapeutics

AKAVA Therapeutics is a biotechnology company developing first-in-class small molecule inhibition therapeutics for neurodegenerative diseases and cancers. Its lead compound AKV9 targets protein aggregation and has been investigated in ALS, hereditary spastic paraplegia, frontotemporal dementia, and Alzheimer's disease. The company was established in 2019 as a commercialization arm for compounds from the Silverman Laboratory at Northwestern University.

drug developmentdrug discovery

ClotProtect Therapeutics Limited is a UK therapeutics spin-out from the University of Leeds developing a first-in-class small molecule anti-fibrinolytic (CP-101) to treat acute haemorrhage. The company is currently in preclinical development, aiming to identify a clinical drug candidate, and its approach promotes clot formation through a novel molecule and mechanism with superior efficacy and potency to the current standard of care (TXA).

drug discoverypreclinical development

FibroNox has pioneered the development of patented first-in-class treatments to mitigate life-threatening fibrotic diseases, including selective Nox4 inhibitors and Nrf2 activators. Its small-molecules have demonstrated efficacy in preclinical studies for halting and reducing established fibrosis. The company focuses on idiopathic pulmonary fibrosis (IPF) as its primary indication, with preclinical data supporting other fibrotic indications, and is developing inhaled therapeutic delivery for pulmonary fibrosis.

inhaled drug deliverypreclinical drug development

FLAG Therapeutics, Inc. is a near-term clinical stage company headquartered in Raleigh, North Carolina, focused on developing new small molecule therapeutics for difficult-to-treat cancers. Its lead candidate, FLAG-003, targets diffuse intrinsic pontine glioma (DIPG) and glioblastoma multiforme (GBM) and is projected to enter Phase 1/2 clinical development in early 2026 in children with DIPG. The company leverages three proprietary drug discovery platforms and holds an exclusive worldwide licensing agreement with Duquesne University.

computer modeling/artificial intelligence in drug discoverydrug developmentdrug discovery